Navigation Links
Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
Date:12/10/2008

SAN CARLOS, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced positive results from the Phase 1 trial of recombinant, secreted protein, NU206, the company's lead compound from its Wnt Therapeutics Program. This single-center, double-blind, placebo-controlled, single-ascending dose (SAD) trial tested the safety, tolerance and pharmacokinetics of a single intravenous (IV) administration of NU206, in 32 healthy male volunteers. Participants were enrolled in four cohorts of varying doses, with a maximum dose of 0.20 mg/kg/day. NU206 had a favorable safety profile, no serious adverse events were observed, and pharmacokinetics were predictable.

"Based on preclinical studies, we believe that NU206 promotes cell growth and repair, and, based also on results from this Phase 1 trial, believe it has the potential to offer a novel approach for the treatment of serious medical conditions such as gastrointestinal (GI) injury, inflammatory bowel disease, and bone disease," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "Because Nuvelo is in the process of merging with ARCA biopharma to create a cardiovascular-focused company, we are currently evaluating partnership and out-licensing opportunities for NU206 to continue development of the compound."

About NU206

NU206 (R-spondin1) is a recombinant, secreted protein that acts as a key regulator of the Wnt pathway, the critical pathway that stimulates cell growth and differentiation during homeostasis and pathogenesis in specific tissues including the GI epithelium and bone. Preclinical studies suggest it can promote growth and repair in animal models of radiation or cancer chemotherapy induced GI injury, inflammatory bowel disease, and bone disease.

About Nuvelo and Kyowa Hakko Kirin's Joint Collaborati
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
4. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
5. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 In ... by FedEx, UPS and The US Postal Service ... specimens classified as ,select agents, by the CDC, ... of handling these sensitive shipments. Marken ... transportation regulations, trained and certified personnel to ensure ...
(Date:8/26/2015)... 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended June 30, 2015. ... dollars and presented under International Financial Reporting Standards ... respect to our Oral Amp B program, rapidly ... said Andrew Rae , President & CEO ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
(Date:8/26/2015)... , August 26, 2015 Israel Proves Its ... wins 1 st place  Wayerz comes in 5 ... Israel by venture capital fund JVP, with Chinese ... US, China , Israel , ... .  Impressive achievement for the Israeli representatives in the ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... to Present at Rodman & Renshaw Annual Global Investment Conference -- BEIJING, Sept. 7 /PRNewswire-Asia-FirstCall/ -- ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... IRVINE, Calif., Sept. 7 ChromaDex Corporation (OTC Bulletin ... company which provides novel and innovative ingredients to the ... a clinical study at The University of Mississippi for ... based on the grant of an exclusive worldwide license ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at the ... at 10:55 a.m. ET / 7:55 a.m. PT ... Healthcare Conference on Tuesday, September 14, 2010 at 11:30 a.m. ... Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will ...
Cached Biology Technology:Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 2Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 3Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 4Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 5Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 6Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 7ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene 2ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene 3
(Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
(Date:8/10/2015)... , August 10, 2015 The latest ... offers comprehensive analysis of the global border security market ... revenues of $16.4bn in 2015. Now: Border security ... an example of the business critical issue you need to ... visiongain ,s objective analysis of how this will impact ...
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... the "twisted ladder," with sugar-phosphate chains making up the "rails" ... halves - seems to be the work of an accomplished ... DNA double helix is the result of random chemical reactions ... arrived at this molecule and its sister molecule, RNA,remains one ...
... the enzyme Akt1 could provide the key to boosting ... of dendritic cells, the immune-system master switches that promote ... at Baylor College of Medicine in a report that ... current issue of the journal Nature Biotechnology. , "By ...
... heard that a new male contraceptive is "five to ten years" ... finally be "yes." This week marked the announcement of one ... opens , Researchers in Italy and at the Population ... compound known as Adjudin (Nature Medicine, Oct. 29). By injecting the ...
Cached Biology News:Uncovering DNA's 'sweet' secret 2Uncovering DNA's 'sweet' secret 3'Super' enzyme may lead way to better tumor vaccines 2Male contraception: One door opens, another closes 2Male contraception: One door opens, another closes 3
Proline-serine-threonine phosphatase-interacting protein 2...
E2F2 protein...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: